Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine.
Multidrug resistant cells are characterized by decreased drug accumulation and retention, thought to be mediated by a high molecular weight glycoprotein, P-glycoprotein (P-gp). Agents such as verapamil have been shown to increase anticancer drug cytotoxicity and increase the amount of drug accumulated and retained by such cells. We show here that in addition to verapamil, reserpine, chloroquine, quinine, quinacrine, yohimbine, vindoline, and catharanthine also enhance the cytotoxicity of vinblastine (VLB) in a multidrug resistant, human leukemic cell line, CEM/VLB1K, described here for the first time. These cells express P-gp as a doublet that is photoaffinity labeled by the analog of VLB, N(p-azido-[3-125I]salicyl)-N'-beta-aminoethylvindesine ([125I]NASV). Both reserpine and, to a lesser extent, verapamil, compete with [125I]NASV for binding to P-gp. We also found that chloroquine, quinacrine, vindoline, and catharanthine, each of which enhanced VLB cytotoxicity in CEM/VLB1K cells by 10- to 15-fold, similarly inhibited [125I]NASV labeling of P-gp. However, neither quinine nor yohimbine inhibited this labeling, and the inhibition produced by catharanthine and vindoline was the greatest or exclusively on the lower band of the P-gp doublet. Our results suggest a complex relationship between the ability of a compound to modulate MDR and its ability to compete for binding to P-gp.
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000345:Affinity Labels / Q000378:metabolism*; D000470:Alkaloids / Q000494:pharmacology*; D001386:Azides / Q000378:metabolism*; D002470:Cell Survival / Q000187:drug effects; D002738:Chloroquine / Q000494:pharmacology; D004347:Drug Interactions; D004351:Drug Resistance; D006801:Humans; D007211:Indoles / Q000494:pharmacology*; D007938:Leukemia / Q000473:pathology*; D008562:Membrane Glycoproteins / Q000378:metabolism*; D010777:Photochemistry; D011796:Quinacrine / Q000494:pharmacology; D011803:Quinine / Q000494:pharmacology; D012110:Reserpine / Q000494:pharmacology; D014700:Verapamil / Q000494:pharmacology; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D014748:Vinca Alkaloids / Q000494:pharmacology; D014751:Vindesine / Q000031:analogs & derivatives* / Q000378:metabolism; D015016:Yohimbine / Q000494:pharmacology
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000345:Affinity Labels; D000470:Alkaloids; D001386:Azides; D007211:Indoles; D008562:Membrane Glycoproteins; D014748:Vinca Alkaloids; C048695:N-(4-azido-3-iodosalicyl)-N'-beta-aminoethylvindesine; D015016:Yohimbine; C009667:vindoline; D014747:Vinblastine; D002738:Chloroquine; D012110:Reserpine; D011803:Quinine; D014700:Verapamil; D011796:Quinacrine; D014751:Vindesine; C017836:catharanthine